# This Page Is Inserted by IFW Operations and is not a part of the Official Record

### **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

#### IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents will not correct images, please do not report the images to the Image Problem Mailbox.

MAR 1 8 Zund

PTO/SB/26 (08-03)

## TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING REJECTION OVER A PRIOR PATENT

Docket Number (Optional) 02307K-141583

In re Application of:

Robert REITER et al.

Application No.

09/855,632

Filed:

May 14, 2001

For:

PSCA: PROSTATE STEM CELL ANTIGEN AND USES THEREOF

The owner, The Regents of the University of California, of one-hundred percent interest in the Instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the Instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 and 173, as presently shortened by any terminal disclaimer, of prior Patent No. 6,258,939 . The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of the prior patent, as presently shortened by any terminal disclaimer, in the event that it later: expires for fallure to pay a maintenance fee, is held unenforceable. Is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all dalms canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

Check either box 1 or 2 below, if appropriate.

1. A For submissions on behalf of an organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the organization.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on Information and betief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

The undersigned is an attorney of record.

Signature

Date

LORELEI DE LARENA

INTELLEGIZATION PROPERTY MANAGER
UCLA Office of Intellectual Property Administration

Terminal disclaimer fee under 37 CFR 1.20(d) is included.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

\*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner). Form PTO/SB/96 may be used for making this certification. See MPEP § 324.



PTO/SB/96 (08-03)

Attorney Docket No. 02307K-1415-83US UC Case no. UC97-575-C

STATEMENT UNDER 37 CFR 3.73(b)
Applicant/Patent Owner: Robert E. Reiter, Owen N. Witte, Douglas F. Saffran and Aya Jakobovits
Application No./Patent No.: 09/855,632 Filed/Issue Date: May 14, 2001
Entitled: PSCA: PROSTATE STEM CELL ANTIGEN AND USES THEREOF
The Regents of the University of California a California comoration  (Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)
states that it is:
1. 🔀 the assignee of the entire right, title, and Interest; or
2. an assignee of less than the entire right, title and interest.  The extent (by, percentage) of its ownership interest is%
in the patent application/patent identified above by virtue of either:
A. An assignment from the Inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel <u>011417</u> , Frame <u>0860</u> , or for which a copy thereof is attached.
AND
B. A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:
1. From: <u>Douglas C. Saffran and Ava Jakobovits</u> To : <u>UroGenesys, Incorporated</u> The document was recorded in the United States Patent and Trademark Office at  Reel <u>011417</u> , Frame <u>0860</u> , or for which a copy thereof is attached.
2. From: UroGenesys, Incorporated To :Agensys, Inc.
The document was recorded in the United States Patent and Trademark Office at
Real, Frame, or for which a copy thereof is attached (re name change).
3. From: Agensys, Inc. To :The Regents of the University of California
The document was recorded in the United States Patent and Trademark Office at
Reel, Frame, or for which a copy thereof is attached.
Additional documents in the chain of title are listed on a supplemental sheet.
Copies of assignments or other documents in the chain of title are attached (re name change).
[NOTE: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.8]
The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.
Date  LORELEI DE LARENA  INTELLECTUAL PROPERTY MANAGER  UCLA OME PARTICULAR PROPERTY MANAGER  UCLA OME PARTICULAR PROPERTY MANAGER
Telephone number  Dr) Dr) Signature
Telephone number
Tite

Attorney Docket No.: 02307K-141583US Client Reference No.: UC97-575-C

#### **ASSIGNMENT**

WHEREAS, Agensys, Inc., a California corporation, having a business address at 1545 17th Street, Santa Monica, California 90404, hereinafter referred to as "ASSIGNOR," is an owner by assignment recorded in the U.S.P.T.O. at reel 011417, frame 0860, of an interest in the below-identified application for United States Letters Patont:

Title of Invention:

PSCA: PROSTATE STEM CELL ANTIGEN AND USES

THEREOF

Filing Date:

May 14, 2001

Scrial No.:


09/855,632

WHEREAS, The Regents of the University of California, a California corporation having a business address at 1111 Franklin Street, 12th Ploor, Oakland, California 94607-5200, hereinafter referred to as "ASSIGNEE," wants to acquire Assignor's interest in the invention and application and in any Letters Patent and Registrations that may be granted on the same;

For good and valuable consideration, receipt of which is hereby acknowledged by Assignor, Assignor has assigned, and by these presents does assign to Assignee all right, title and interest in and to the invention and application and to all foreign counterparts (including patent, utility model and industrial designs), and in and to any Letters Patent and Registrations which may hereafter be granted on the same in the United States and all countries throughout the world, and to claim the priority from the application as provided by the Paris Convention. The right, title and interest is to be held and enjoyed by Assignee and Assignee's successors and assigns as fully and exclusively as it would have been held and enjoyed by Assignor had this assignment not been made, for the full term of any Letters Patent and Registrations which may be granted thereon, or of any division, renewal, continuation in whole or in part, substitution, conversion, reissue, prolongation or extension thereof.

Assignor further agrees that Assignor will, without charge to Assignee, but at Assignee's expense, (a) cooperate with Assignee in the prosecution of U.S. Patent applications and foreign counterparts on the invention and any improvements, (b) execute, verify, acknowledge and deliver all such further papers, including patent applications and instruments of transfer and (c) perform such other acts as Assignee lawfully may request to obtain or maintain Letters Patent and Registrations for the invention and improvements in any and all countries, and to vest title thereto in Assignee, or Assignee's successors and assigns.

title thereto in Assignee, or Assignee's successors an	d assigns.
IN TESTIMONY WHEREOF, this	BY: Aya Jelobate  Title: Senior VP, Technolog & Corporate Dovelopent.
acknowledged to me that lar/she executed the same the instrument the person, or the entity upon behalf of	before me, Tracy in Dolan.  personally known to me for proved to me on the whose name is subscribed to the within instrument, and in his/her authorized capacity, and that by his/her signature on of which the person acted, executed the instrument.
WITNESS my hand and official seal.	Juny M. Dolan NOTARY PUBLIC
My Commission Expires: 4/8/05 60116665 v1	TRACY M. DOLAN COMM. # 1300038 HOTARY PUBLIC & CALIFORNA TO COMMIT LOS ANGELES COUNTY COMMIT, EXD. APRIL 8, 2005



MAR 1 8 2004 P

OTATELEENIT	HUDED AT	AFD 4 74	/L \
STATEMENT	UNDER 3/	UFK 3./3	נטו

Applicant/Patent Owner: Robert E. Reiter, Lwen N. Witte, Douglas F. Saffran and Aya Jakobovits
Application No./Patent No.: 09/855,632 Filed/Issue Date: May 14, 2001
Entitled: PSCA: PROSTATE STEM CELL ANTIGEN AND USES THEREOF
The Regents of the University of California , a California corporation
(Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.
states that it is:
1.  the assignee of the entire right, title, and interest; or
an assignee of less than the entire right, title and interest.  The extent (by, percentage) of its ownership interest is%
in the patent application/patent identified above by virtue of either:
A. An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel <u>011417</u> , Frame <u>0860</u> , or for which a copy thereof is attached.
OR
B. A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:
1. From: To :
The document was recorded in the United States Patent and Trademark Office at
Reel, Frame, or for which a copy thereof is attached.
2. From: To :
The document was recorded in the United States Patent and Trademark Office at
Reel, Frame, or for which a copy thereof is attached.
3. From: To :
The document was recorded in the United States Patent and Trademark Office at
Reel, Frame, or for which a copy thereof is attached.
Additional documents in the chain of title are listed on a supplemental sheet.
Copies of assignments or other documents in the chain of title are attached.  [NOTE: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.8]
The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.
October 20, 2003 Lorelei de Larena
Date  Typed or printed name
310) 794-0558
Telephone number Signature
UCLA Intellectual Property Manage





Attorney Docket No. 02307K-1415-83US UC Case no. UC97-575-C

STATEMENT UNDER 37 CFR 3.73(b)			
Applicant/Patent Owner: Robert E. Reiter, Lwen N. Witte, Douglas F. Saffran and Aya Jakobovits			
Application No./Patent No.: 09/855,632 Filed/Issue Date: May 14, 2001			
Entitled: PSCA: PROSTATE STEM CELL ANTIGEN AND USES THEREOF			
Agensys, Inc. , a California corporation			
(Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)			
states that it is:			
1. the assignee of the entire right, title, and interest; or			
<ol> <li>an assignee of less than the entire right, title and interest.</li> <li>The extent (by, percentage) of its ownership interest is%</li> </ol>			
in the patent application/patent identified above by virtue of either:			
A.  An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel, Frame, or for which a copy thereof is attached.			
OR			
B. A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:			
1. From: <u>Douglas C. Saffran and Aya Jakobovits</u> To : <u>UroGenesys, Incorporated</u> The document was recorded in the United States Patent and Trademark Office at Reel <u>011417</u> , Frame <u>0860</u> , or for which a copy thereof is attached.			
2. From: <u>UroGenesys, Incorporated</u> To : <u>Agensys, Inc.</u>			
The document was recorded in the United States Patent and Trademark Office at Reel, Frame, or for which a copy thereof is attached (re name change).			
3. From: To :			
The document was recorded in the United States Patent and Trademark Office at Reel, Frame, or for which a copy thereof is attached.			
Additional documents in the chain of title are listed on a supplemental sheet.			
☑ Copies of assignments or other documents in the chain of title are attached (re name change).  [NOTE: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.8]			
The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.			
10/21/03 Tracy M. Dolan			
Date  310-820-8029  Tolephone number  Signature			
Asst. Corporate Secretary Title			